Literature DB >> 23395224

Association between polymorphisms in interleukin-4Rα and interleukin-13 and glioma risk: a meta-analysis.

Guan Sun1, Xiefeng Wang, Lei Shi, Xiao Yue, Linshan Fu, Chen Chen, Zhengyi Li, Tianhong Pan, Zhengqiang Wan.   

Abstract

INTRODUCTION: It has been suggested that allergies are inversely associated with glioma risk. Single nucleotide polymorphisms in two allergy-related genes [interleukin (IL)-4Rα, IL-13] have been implicated in susceptibility to glioma; however, results from the published studies remained inconclusive.
METHODS: To derive a more precise relationship, we conducted a meta-analysis including seven case-control studies that investigated the influence of IL-4Rα rs1801275 and IL13 rs20541 polymorphisms on glioma risk. Data were extracted from these studies and pooled odds ratios (OR) with 95% confidence intervals (CI) were used to investigate the strength of the association.
RESULTS: Overall, the pooled analysis showed that there was no significant association between the IL-4Rα rs1801275 polymorphism and glioma risk (OR = 0.99, 95%CI: 0.79-1.25, AG/GG vs. AA). However, we found that the IL13 rs20541 variant genotypes (GA/AA) were significantly associated with reduced risk for glioma (OR = 0.85, 95%CI: 0.75-0.97, GA/AA vs. GG). In the stratified analyses by ethnicity, marginally significant association between the IL13 rs20541 polymorphism and decreased glioma risk was found among Asian populations in dominant models (OR = 0.84, 95%CI: 0.70-1.00, GA/AA vs. GG).
CONCLUSIONS: This meta-analysis suggests that the IL13 rs20541 but not the IL-4Rα rs1801275 polymorphism may be a genetic predictor for glioma. More studies with larger sample size are warranted to further elucidate the impact of the IL13 rs20541 polymorphism on glioma risk.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23395224     DOI: 10.1016/j.canep.2013.01.003

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  8 in total

1.  Association of the interleukin-4Rα rs1801275 and rs1805015 polymorphisms with glioma risk.

Authors:  Jun Guo; Lei Shi; Min Li; Jin Xu; Shushan Yan; Chuang Zhang; Guan Sun
Journal:  Tumour Biol       Date:  2013-08-27

2.  Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis.

Authors:  Peiqin Chen; Chao Chen; Kun Chen; Tao Xu; Chun Luo
Journal:  Tumour Biol       Date:  2014-12-04

3.  Commentary: IL-4 and IL-13 receptors and signaling.

Authors:  Sarah M McCormick; Nicola M Heller
Journal:  Cytokine       Date:  2015-07-14       Impact factor: 3.861

Review 4.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

5.  Association of single-nucleotide polymorphisms in ERCC1 and ERCC2 with glioma risk.

Authors:  Lei Hui; Shuangzhu Yue; Guojun Gao; Haigang Chang; Xiangsheng Li
Journal:  Tumour Biol       Date:  2014-05-01

6.  Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis.

Authors:  Narges Seyfizadeh; Tohid Kazemi; Mehdi Farhoudi; Mohammad Reza Aliparasti; Homayoun Sadeghi-Bazargani; Shohreh Almasi; Zohreh Babaloo
Journal:  Am J Clin Exp Immunol       Date:  2014-12-05

7.  Association between polymorphism of the interleukin-13 gene and susceptibility to hepatocellular carcinoma in the Chinese population.

Authors:  Yan Deng; Ming Xie; Li Xie; Jian Wang; Taijie Li; Yu He; Ruolin Li; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  Genetic association between selected cytokine genes and glioblastoma in the Han Chinese population.

Authors:  Tianbo Jin; Xiaolan Li; Jiayi Zhang; Hong Wang; Tingting Geng; Gang Li; Guodong Gao; Chao Chen
Journal:  BMC Cancer       Date:  2013-05-12       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.